EGFR and non-small cell lung carcinoma: Osimertinib, developed to treat drug-resistant non-small cell lung cancer, can inhibit epidermal growth factor receptor (EGFR) tyrosine kinase by MAR with its Cys797 residues on the site reactive to adenosine triphosphate (ATP) (Dong et al., 2018).